**EMBARGOED BY BMC GLOBAL AND PUBLIC HEALTH UNTIL JULY 1 st , 7PM ET/ 5 PM MST/ 4PM PST** Newswise — Genital herpes infections and their related complications lead to billions of dollars in health care expenditures and productivity losses globally, according to the first ever global estimates of the economic costs of these conditions. The paper, which publishes July 1 st in the journal BMC Global and Public Health, calls for greater investment in prevention of herpes transmission, including concerted efforts to develop effective vaccines against this common virus. Corresponding author Nathorn Chaiyakunapruk, PharmD, PhD, professor of pharmacotherapy, and Haeseon Lee, PharmD, research fellow in pharmacotherapy, both at the College of Pharmacy of University of Utah Health, performed the research in collaboration with the World Health Organization and other academic institutions.
They detail the associated economic cost estimates for genital herpes globally and by region. The findings underscore the critical need for accelerated development of effective HSV vaccines, according to the authors. Current treatments, such as antiviral drugs, can alleviate symptoms but do not prevent transmission or recurrence of the infection.
A safe and effective vaccine could significantly reduce the health and economic burden of HSV infections globally, the authors say. Herpes is caused by infection with one of two types of the herpes simplex virus (HSV). Around two thirds of people (67%) aged 0.
